Company intelligence / Profile preview

GlycoGenesys, Inc.

Boston, Massachusetts, United Statesbloomberg.com ↗

Ownership: Private
Development stage: Phase 1

Overview

GlycoGenesys was a Boston-based biotechnology company focused on developing carbohydrate-based therapeutics for cancer. Its lead candidate, GCS‑100, advanced through Phase I/II clinical trials in multiple myeloma and CLL and completed earlier-stage studies in solid tumors such as pancreatic and colorectal cancers. The company filed for Chapter 11 bankruptcy protection in early 2006 after financial difficulties stalled further development of its pipeline. No products reached commercialization.

Therapeutic areas: Oncology
Modalities: Small molecules (carbohydrate-based drugs)
Industry: Biotech

Drug pipeline

1 asset

GCS-100

Beyond the preview

Go deeper on GlycoGenesys, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlycoGenesys, Inc..

Explore the full profile